Suppr超能文献

供体性别以及供受体性别差异并不影响活体肝移植后肝细胞癌的复发。

Donor sex and donor-recipient sex disparity do not affect hepatocellular carcinoma recurrence after living donor liver transplantation.

作者信息

Oh Rak Kyun, Hwang Shin, Song Gi-Won, Ahn Chul-Soo, Moon Deok-Bog, Ha Tae-Yong, Jung Dong-Hwan, Park Gil-Chun, Yoon Young-In, Kang Woo-Hyoung

机构信息

Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

出版信息

Ann Surg Treat Res. 2023 Sep;105(3):133-140. doi: 10.4174/astr.2023.105.3.133. Epub 2023 Sep 1.

Abstract

PURPOSE

Studies have yielded contradictory results on whether donor sex and donor-recipient sex disparity affect hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation (LDLT). The present study assessed whether donor sex or donor-recipient sex disparity affects HCC recurrence after LDLT at a high-volume center.

METHODS

This study included 772 HCC patients who underwent LDLT between January 2006 and December 2015 at Asan Medical Center. Patients were divided into 4 groups based on the sex of the donor and recipient: male-to-male (n = 490, 63.5%), male-to-female (n = 75, 9.7%), female-to-male (n = 170, 22.0%), and female-to-female (n = 37, 4.8%).

RESULTS

Disease-free survival (DFS; P = 0.372) and overall survival (OS; P = 0.591) did not differ significantly among the 4 groups. DFS also did not differ significantly between LDLT recipients with male and female donors (P = 0.792) or between male and female recipients (P = 0.084). After patient matching with an α-FP/des-γ-carboxy prothrombin/tumor volume score cutoff of 5logs, donor-recipient sex disparity did not significantly affect DFS (P = 0.598) or OS (P = 0.777). There were also no differences in DFS in matched LDLT recipients with male and female donors (P = 0.312) or between male and female recipients (P = 0.374).

CONCLUSION

Neither donor sex nor donor-recipient sex disparity significantly affected posttransplant HCC recurrence.

摘要

目的

关于供体性别及供受体性别差异是否影响活体肝移植(LDLT)后肝细胞癌(HCC)复发,各项研究结果相互矛盾。本研究评估了在一个高容量中心,供体性别或供受体性别差异是否会影响LDLT后HCC复发。

方法

本研究纳入了2006年1月至2015年12月在峨山医学中心接受LDLT的772例HCC患者。根据供体和受体的性别将患者分为4组:男性供体至男性受体(n = 490,63.5%)、男性供体至女性受体(n = 75,9.7%)、女性供体至男性受体(n = 170,22.0%)和女性供体至女性受体(n = 37,4.8%)。

结果

4组之间的无病生存期(DFS;P = 0.372)和总生存期(OS;P = 0.591)无显著差异。LDLT受体中,男性供体与女性供体之间(P = 0.792)或男性受体与女性受体之间(P = 0.084)的DFS也无显著差异。在根据α-甲胎蛋白/去γ-羧基凝血酶原/肿瘤体积评分截断值为5对数进行患者匹配后,供受体性别差异对DFS(P = 0.598)或OS(P = 0.777)无显著影响。在匹配的LDLT受体中,男性供体与女性供体之间(P = 0.312)或男性受体与女性受体之间(P = 0.374)的DFS也无差异。

结论

供体性别和供受体性别差异均未显著影响移植后HCC复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验